|
|
Office Locations:
|
55 Railroad Ave. #300
Greenwich, CT 06830
Phone: 203-863-5000
| |
|
|
|
|
Financial Services
Food & Agriculture
Life Sciences & Healthcare
|
|
|
Viking Global Investors LP is a global investment firm founded in 1999. The firm manages approximately $50 billion of capital for our investors. Viking has offices in Greenwich, New York, Hong Kong, London and San Francisco and is registered as an investment adviser with the U.S. Securities and Exchange Commission. The firm uses fundamental analysis to select investments, primarily public and private equity interests, across industries and geographies. Viking generally invests in companies based on a thorough assessment of their business models and fundamentals, the quality of their management teams and cyclical and secular industry trends.
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|
|
Name | |
| |
Title | |
|
David Truetzel | |
| |
Analyst | |
Hans Reuter | |
| |
| |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
10/02/2024
|
Triveni Bio
|
MA
|
$115,000,000
|
Series B
|
07/19/2024
|
Antheia
|
CA
|
$17,000,000
|
|
06/11/2024
|
AlphaSense
|
NY
|
$650,000,000
|
Venture
|
04/03/2024
|
Diagonal Therapeutics
|
MA
|
$128,000,000
|
Series A
|
03/06/2024
|
Sionna Therapeutics
|
MA
|
$182,000,000
|
Series C
|
02/13/2024
|
Areteia Therapeutics
|
NC
|
$75,000,000
|
Series A
|
02/08/2024
|
Neurona Therapeutics
|
CA
|
$120,000,000
|
Venture
|
01/04/2024
|
Human Immunology Biosciences
|
CA
|
$95,000,000
|
Series B
|
12/19/2023
|
Lightmatter
|
CA
|
$155,000,000
|
Series C-2
|
|
|
|
|
|